CA2374295A1 - Il-8 receptor antagonists - Google Patents
Il-8 receptor antagonists Download PDFInfo
- Publication number
- CA2374295A1 CA2374295A1 CA002374295A CA2374295A CA2374295A1 CA 2374295 A1 CA2374295 A1 CA 2374295A1 CA 002374295 A CA002374295 A CA 002374295A CA 2374295 A CA2374295 A CA 2374295A CA 2374295 A1 CA2374295 A1 CA 2374295A1
- Authority
- CA
- Canada
- Prior art keywords
- cr8r8
- alkyl
- 4alkyl
- optionally substituted
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13666599P | 1999-05-28 | 1999-05-28 | |
US60/136,665 | 1999-05-28 | ||
PCT/US2000/014660 WO2000072840A1 (en) | 1999-05-28 | 2000-05-26 | Il-8 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2374295A1 true CA2374295A1 (en) | 2000-12-07 |
Family
ID=22473833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002374295A Abandoned CA2374295A1 (en) | 1999-05-28 | 2000-05-26 | Il-8 receptor antagonists |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1180025A4 (ja) |
JP (1) | JP2003500443A (ja) |
KR (1) | KR20020016806A (ja) |
CN (1) | CN1352554A (ja) |
AR (1) | AR029361A1 (ja) |
AU (1) | AU766999B2 (ja) |
BR (1) | BR0010863A (ja) |
CA (1) | CA2374295A1 (ja) |
CO (1) | CO5170528A1 (ja) |
CZ (1) | CZ20014246A3 (ja) |
HK (1) | HK1045256A1 (ja) |
HU (1) | HUP0201302A3 (ja) |
IL (1) | IL146053A0 (ja) |
MX (1) | MXPA01012267A (ja) |
NO (1) | NO20015774D0 (ja) |
NZ (1) | NZ514728A (ja) |
PL (1) | PL351947A1 (ja) |
TR (1) | TR200103354T2 (ja) |
WO (1) | WO2000072840A1 (ja) |
ZA (1) | ZA200109627B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1413302A3 (en) * | 1999-07-21 | 2004-05-12 | Kadmus Pharmaceuticals, Inc. | Substituted guanidines for the treatment of pain |
US6875759B1 (en) | 1999-07-21 | 2005-04-05 | Kadmus Pharmaceuticals | Substituted guanidines and the use thereof |
AU6230300A (en) * | 1999-07-21 | 2001-02-13 | Kadmus Pharmaceuticals, Inc. | Substituted guanidines and the use thereof |
WO2002070467A1 (en) | 2001-02-26 | 2002-09-12 | 4Sc Ag | Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments |
DE10109204A1 (de) * | 2001-02-26 | 2002-09-19 | 4Sc Ag | Verbindungen zur Behandlung von Protozoen-Erkrankungen |
CA2522817A1 (en) | 2003-05-01 | 2004-11-11 | F. Hoffmann-La Roche Ag | Imidazolin-2-ylaminophenyl amides as ip antagonists |
CN101531621B (zh) * | 2009-04-14 | 2012-08-15 | 厦门康奥克科技有限公司 | 一种胍类化合物的制备方法 |
JP2021501198A (ja) * | 2017-10-27 | 2021-01-14 | トランスフュージョン ヘルス,リミティド ライアビリティ カンパニー | フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US605977A (en) * | 1898-06-21 | Bruno richard seifert | ||
US1953494A (en) * | 1926-08-26 | 1934-04-03 | Ig Farbenindustrie Ag | Process of preparing substituted guanidines |
US3914306A (en) * | 1972-09-22 | 1975-10-21 | Rorer Inc William H | Guanidines |
US5696290A (en) * | 1994-09-12 | 1997-12-09 | Monsanto Company | Synthesis of penta-substituted guanidines |
EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
AR008290A1 (es) * | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. |
WO2000072800A2 (en) * | 1999-05-28 | 2000-12-07 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
UY26627A1 (es) * | 2000-03-24 | 2001-09-28 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
-
2000
- 2000-05-24 CO CO00038191A patent/CO5170528A1/es not_active Application Discontinuation
- 2000-05-24 AR ARP000102556A patent/AR029361A1/es unknown
- 2000-05-26 WO PCT/US2000/014660 patent/WO2000072840A1/en not_active Application Discontinuation
- 2000-05-26 AU AU51690/00A patent/AU766999B2/en not_active Ceased
- 2000-05-26 CN CN00808133A patent/CN1352554A/zh active Pending
- 2000-05-26 PL PL00351947A patent/PL351947A1/xx not_active Application Discontinuation
- 2000-05-26 IL IL14605300A patent/IL146053A0/xx unknown
- 2000-05-26 BR BR0010863-4A patent/BR0010863A/pt not_active IP Right Cessation
- 2000-05-26 HU HU0201302A patent/HUP0201302A3/hu unknown
- 2000-05-26 JP JP2000620952A patent/JP2003500443A/ja not_active Withdrawn
- 2000-05-26 MX MXPA01012267A patent/MXPA01012267A/es unknown
- 2000-05-26 TR TR2001/03354T patent/TR200103354T2/xx unknown
- 2000-05-26 EP EP00936368A patent/EP1180025A4/en not_active Withdrawn
- 2000-05-26 KR KR1020017015176A patent/KR20020016806A/ko not_active Application Discontinuation
- 2000-05-26 NZ NZ514728A patent/NZ514728A/en not_active Application Discontinuation
- 2000-05-26 CA CA002374295A patent/CA2374295A1/en not_active Abandoned
- 2000-05-26 CZ CZ20014246A patent/CZ20014246A3/cs unknown
-
2001
- 2001-11-22 ZA ZA200109267A patent/ZA200109627B/xx unknown
- 2001-11-27 NO NO20015774A patent/NO20015774D0/no not_active Application Discontinuation
-
2002
- 2002-07-18 HK HK02105335.1A patent/HK1045256A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TR200103354T2 (tr) | 2002-06-21 |
AU5169000A (en) | 2000-12-18 |
WO2000072840A1 (en) | 2000-12-07 |
KR20020016806A (ko) | 2002-03-06 |
NO20015774L (no) | 2001-11-27 |
JP2003500443A (ja) | 2003-01-07 |
CZ20014246A3 (cs) | 2002-05-15 |
NO20015774D0 (no) | 2001-11-27 |
ZA200109627B (en) | 2002-11-28 |
HK1045256A1 (zh) | 2002-11-22 |
HUP0201302A2 (hu) | 2002-12-28 |
PL351947A1 (en) | 2003-07-14 |
HUP0201302A3 (en) | 2003-02-28 |
CO5170528A1 (es) | 2002-06-27 |
IL146053A0 (en) | 2002-07-25 |
BR0010863A (pt) | 2002-02-19 |
EP1180025A4 (en) | 2002-08-28 |
NZ514728A (en) | 2004-04-30 |
EP1180025A1 (en) | 2002-02-20 |
AU766999B2 (en) | 2003-10-30 |
MXPA01012267A (es) | 2002-07-30 |
CN1352554A (zh) | 2002-06-05 |
AR029361A1 (es) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6133319A (en) | IL-8 receptor antagonists | |
US6300325B1 (en) | IL-8 receptor antagonists | |
US6271261B1 (en) | IL-8 receptor antagonists | |
US6218539B1 (en) | IL-8 receptor antagonists | |
US6204294B1 (en) | IL-8 receptor antagonists | |
CA2401659A1 (en) | Il-8 receptor antagonists | |
US6166055A (en) | Benzoisothiazole compounds useful as IL-8 receptor antagonists | |
AU766082B2 (en) | IL-8 receptor antagonists | |
AU766999B2 (en) | IL-8 receptor antagonists | |
US6335352B1 (en) | IL-8 receptor antagonists | |
US6248785B1 (en) | IL-8 receptor antagonists | |
US6177448B1 (en) | IL-8 receptor antagonists | |
WO2000072800A2 (en) | Il-8 receptor antagonists | |
JP2000515495A (ja) | Il―8レセプターアンタゴニスト | |
EP0920253A1 (en) | Il-8 receptor antagonists | |
WO2000073282A1 (en) | Il-8 receptor antagonists | |
WO2000069435A1 (en) | Il-8 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |